Company Overview and News

1
Your Daily Pharma Scoop: GW Pharmaceuticals' Epidiolex, Alnylam Data, Johnson & Johnson's Q1 Results

2018-04-18 seekingalpha
Today, we will discuss GW Pharmaceuticals (NASDAQ:GWPH), which is up more than 10% after the FDA released briefing documents ahead of the Ad Com meeting to review GWPH's NDA for Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients 2 years or older.

 
BGNE / BeiGene, Ltd. FORM 8-K (Current Report)

2018-04-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT

 
BRIEF-Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American Association For Cancer Research Annual Meeting

2018-04-16 reuters
* BEIGENE PRESENTS CLINICAL DATA ON PAMIPARIB IN CHINESE PATIENTS WITH OVARIAN CANCERS OR TRIPLE-NEGATIVE BREAST CANCER AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

 
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas

2018-04-16 globenewswire
CAMBRIDGE, Mass. and BEIJING, China, April 16, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, announced today that the first patient was dosed in a global Phase 2 clinical trial of tislelizumab, an investigational anti-PD-1 antibody, in patients with relapsed or refractory mature T- and natural killer (NK)-cell lymphomas.

 
Week In Review: Ping An Good Doctor Plans $1 Billion Hong Kong IPO In Mid-May

2018-04-15 seekingalpha
Ping An Insurance (Group) (OTCPK:PIAIF) (OTCPK:PNGAY) plans to carve out its Ping An Healthcare and Technology (also known as Ping An Good Doctor APP) and IPO in Hong Kong for $1 billion at a valuation of $5 billion. The company plans to go public in the middle of May. In May 2016, Ping An Healthcare and Technology raised $500 million in a Series A. In December 2017, the company raised $400 million from Softbank Union in a pre-IPO round.

 
Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data

2018-04-11 seekingalpha
Today we will discuss vTv Therapeutics (NASDAQ:VTVT), which has seen three quarters of its market capitalization wiped off after the failure of a late-stage Alzheimer’s study. The failure once again highlights the fact that Alzheimer’s remains a difficult to treat area.

 
BGNE / BeiGene, Ltd. FORM 8-K (Current Report)

2018-04-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT

 
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma

2018-04-10 globenewswire
CAMBRIDGE, Mass. and BEIJING, China, April 10, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the first patient was dosed in a global Phase 2 clinical trial of tislelizumab, an investigational anti-PD-1 antibody, in patients with previously treated advanced hepatocellular carcinoma (HCC or liver cancer).

 
BeiGene Appoints J. Samuel Su to its Board of Directors

2018-04-03 globenewswire
BEIJING, China and CAMBRIDGE, Mass., April 03, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the appointment of J. Samuel (Sam) Su to its Board of Directors.

 
Celgene Corporation Looks Cheap, Considering Its Potential

2018-03-23 investorplace
When it comes to biotech stocks, the volatility is often stomach-churning. It’s not uncommon to see a company’s valuation plunge 50% or more, such as when there is a bad clinical trial. But this kind of risk is usually for the smaller operators, which have limited sources and little or no revenues.

8
Biotechs Approaching New Waters

2018-03-20 seekingalpha
The biotech sector also continues to benefit from potential M&A, faster drug approvals, strong risk appetite, and improving public sentiment.

1
Clovis Is The Investor's PARPi Winner

2018-03-16 seekingalpha
As investors, we should be comparing these three to find the best value and possible ROI.

 
BGNE / BeiGene, Ltd. 10-K (Annual Report)

2018-02-28 sec.gov
bgne-Current_Folio_10K Table of Contents

 
BGNE / BeiGene, Ltd. S-8

2018-02-28 sec.gov
As filed with the Securities and Exchange Commission on February 28, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BEIGENE, LTD. (Exact name of registrant as specified in its charter) Cayman Islands Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 07725L102